Introduction
Improved outcomes for normoglycaemic patients suffering acute myocardial infarction (AMI) over the last decade have not been matched by similar improvements in mortality for diabetic patients despite similar levels of baseline risk and appropriate medical therapy. The reasons for this disparity in outcome are not completely understood.
Purpose
The purpose of this study was to determine if peri-infarct glycaemic control has an impact on myocardial infarct size, left ventricular ejection fraction (LVEF) and prognosis.
Methods
Ninety-three patients with first acute myocardial infarction (AMI) were studied. 22 patients had diabetes mellitus (DM) based on prior history or admission blood glucose ≥ 11.1 mmol/l. 13 patients had dysglycaemia (admission blood glucose ≥ 7.8 mmol/l but <11.1 mmol/l) and 58 patients had normoglycaemia (admission blood glucose <7.8 mmol/l). Patients underwent CMR imaging at index presentation and at median follow-up of 11 months. The CMR protocol was identical for all patients and included cine imaging and late gadolinium enhancement.
Results
Patients with dysglycaemia and DM had larger infarct sizes by CMR than normoglycaemic patients, at baseline (mean (standard deviation, SD) % LV scar 23.0 (10.9), 25.6 (12.9) and 15.8 (10.3) respectively, overall p = 0.001) and at 11 months (mean (SD) % LV scar 17.6 (8.9), 19.1 (9.6) and 12.4 (7.8) respectively, overall p = Graph demostrating mean % LV scar at baseline and at median follow up 11 months accordeing to glycaemic status Figure 1 Graph demostrating mean % LV scar at baseline and at median follow up 11 months accordeing to glycaemic status. The error bars represent the 95% confidence intervals.
0.017) (Figure 1 ). Patients with dysglycaemia and DM also had lower LVEF than normoglycaemic patients at baseline and at 11 months (not significant) and had lower event-free survival at 18 months (p = 0.005) (Figure 2 ).
Conclusion
This study highlights the prognostic significance of periinfarct glycaemic control in patients with AMI. Patients with dysglycaemia or DM appear to have larger infarct sizes and lower LVEF as determined by CMR, than normoglycaemic patients. This may, in part, account for their adverse prognosis.
Kaplan-Meier curves demonstratin event-free survival for all patients subdivided by glycaemic status Figure 2 Kaplan-Meier curves demonstratin event-free survival for all patients subdivided by glycaemic status.
